Study of the Association of Nonalcoholic Fatty Liver Disease With Colorectal Malignant Neoplasm (NWC)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ming-Hua Zheng, Wenzhou Medical College
ClinicalTrials.gov Identifier:
NCT01657773
First received: July 29, 2012
Last updated: August 3, 2012
Last verified: August 2012
  Purpose

The aim of this sudy is to investigate the prevalence of colorectal cancer (CRC) in patients with nonalcoholic fatty liver disease (NAFLD) and evaluate whether NAFLD is a risk factor for CRC.


Condition Intervention
Colorectal Neoplasms
Nonalcoholic Fatty Liver Disease
Other: Ultrasound examination and Colonoscopy examination

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Study of the Prevalence of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease.

Resource links provided by NLM:


Further study details as provided by Wenzhou Medical University:

Primary Outcome Measures:
  • Ultrasound examination [ Time Frame: Up to 10 months ] [ Designated as safety issue: No ]
    Hepatic ultrasonography scanning was performed on all patients by experienced radiologists who were blinded to the aims of the study and clinical details of the patients. NAFLD was diagnosed by the following criterion: hepatomegaly, the echogenicity of liver parenchyma increased diffusely, and vascular blurring.

  • Colonoscopy examination [ Time Frame: Up to 10 months ] [ Designated as safety issue: No ]

    Before performed colonoscopy examination, all patients were given 4L polyethelyne glycol lavage solution for bowel preparation.

    The colonoscopic features include the types, location, size, number of lesions and differentiation of neoplasm.


  • Statistical analysis [ Time Frame: Up to 07 months ] [ Designated as safety issue: No ]
    The Binary logistic regression analysis was applied to assay the correlation between NAFLD and CRC after adjustment for independent factors, including age, gender, smoking, and family history.


Secondary Outcome Measures:
  • Patients' baseline characteristics [ Time Frame: Up to 10 months ] [ Designated as safety issue: No ]
    Patients' baseline characteristics were collected before colonoscopy examination. Smoking, alcohol consumption, past medical history, and family history were all recorded using a standardized questionnaire.Blood pressure (BP) was measured in rest state with a standard mercury sphygmomanometer.

  • Laboratory Assay and Measurement [ Time Frame: Up to 10 months ] [ Designated as safety issue: No ]
    Complete blood count, liver function, blood glucose , blood lipids, Cancer Embryo Antigen (CEA) and other related test were performed when underwent colonoscopy examination. The liver function test included alanine aminotranferase, aspartate aminotranferase, albumin, serum sodium, serum chloride, serum chloride and creatinine. Complete blood count was made up of platelet and hemoglobin (Hb). Blood lipids test contains, total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. Additionally, CEA was detected by conventional serological assays.


Enrollment: 2315
Study Start Date: April 2012
Study Completion Date: July 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
colorectal cancer, without nonalcoholic fatty liver disease
Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had not been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination.
Other: Ultrasound examination and Colonoscopy examination
colorectal cancer, with nonalcoholic fatty liver disease
Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination ultrasonography.
Other: Ultrasound examination and Colonoscopy examination

Detailed Description:

As one of the most common cancer worldwide, colorectal cancer (CRC) is a major cause of cancer death in Asian countries. And during the past three decades, the incidence of CRC has been increasing rapidly in china. Many studies supported that cigarette smoking, obesity and insulin resistance were associated with CRC. In recent years, metabolic syndrome (MetS) - Including glucose tolerance, dyslipidemia, obesity, hypertension and chronic inflammation - and its individual components have been proven to be the risk for colorectal neoplasm. Colonoscopy is the most accurate technique for diagnosis, surveillance and exclusion of colorectal neoplasm for high-risk CRC groups. Therefore, improved risk stratification knowledge of the target population is necessary to improve CRC patients' prognosis.

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide and cause a wide spectrum of liver damage, such as steatohepatitis, cirrhosis, even end-stage liver disease and hepatocellular carcinoma. NAFLD has been found to be associated with obesity, insulin resistance, hypertension and dyslipidemia, and is considered as a liver manifestation of MetS. Although it has been also well established that MetS and its individual components are risk factors for colorectal neoplasm, as above, there is paucity of research looking at the relation between NAFLD and CRC. Therefore, the investigators aimed to investigate the prevalence of CRC in patients with NAFLD and evaluate whether NAFLD is an independent risk factor for CRC.

  Eligibility

Ages Eligible for Study:   10 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

The study population consisted entirely of outpatients. Patients were offered to perform colonoscopy for CRC screening according to the American College of Gastroenterology recommendations. Based on blood tests and abdomen B ultrasonography, patients without NAFLD were regarded as healthy controls and those with NAFLD constituted the community NAFLD cohort. Patients were included only if they had colonoscopy and conventional inspections (blood routine, liver function test and abdomen B ultrasonography). Among them who with history of colorectal cancers or polyps, other extraintestinal malignancies and contraindications to colonoscopy were excluded. Besides, we excluded patients who had viral hepatitis, cirrhosis, liver cancer or other liver disease.Patients who drank more than 20g alcohol per day were also excluded.

Criteria

Inclusion Criteria:

  • Patients had colonoscopy and
  • Patients had conventional inspections(blood routine, liver function test and abdomen B ultrasonography)

Exclusion Criteria:

  • Patients were excluded with history of colorectal cancers or polyps, other extraintestinal malignancies and contraindications to colonoscopy.
  • Patients were excluded who had viral hepatitis, cirrhosis, liver cancer or other liver disease.
  • Patients ere excluded who drank more than 20g alcohol per day.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01657773

Locations
China, Zhejiang
Wenzhou Medical College
Wenzhou, Zhejiang, China, 325000
Sponsors and Collaborators
Wenzhou Medical University
Investigators
Study Chair: MingHua Zheng, Medical Master First Affiliated Hospital of Wenzhou Medical College
Principal Investigator: XianFeng Lin, Medical undergraduate Wenzhou Medical University
Principal Investigator: KeQing Shi, Medical Master First Affiliated Hospital of Wenzhou Medical College
Principal Investigator: WenYue Liu, Medical undergraduate First Affiliated Hospital of Wenzhou Medical College
  More Information

No publications provided by Wenzhou Medical University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ming-Hua Zheng, Attending physician, Wenzhou Medical College
ClinicalTrials.gov Identifier: NCT01657773     History of Changes
Other Study ID Numbers: wenzhouMC 001
Study First Received: July 29, 2012
Last Updated: August 3, 2012
Health Authority: China: Ethics Committee

Additional relevant MeSH terms:
Neoplasms
Colorectal Neoplasms
Fatty Liver
Liver Diseases
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases

ClinicalTrials.gov processed this record on September 14, 2014